Financials data is unavailable for this security.
View more
Year on year Kyverna Therapeutics Inc 's revenues fell -100.00% from 7.03m to 0.00. has fallen 108.93% from a loss of 28.89m to a larger loss of 60.37m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Kyverna Therapeutics Inc fell by 3.08m. Cash Flow from Financing totalled 58.12m or -- of revenues. In addition the company used 52.41m for operations while cash used for investing totalled 8.79m.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 7.73 |
---|---|
Tangible book value per share | 7.73 |
More ▼
Balance sheet in USDView more
Current ratio | 14.86 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.0042 |
---|---|
Total debt/total capital | 0.0042 |
More ▼